Current Report · Items 5.02, 7.01, 9.01 · 8-K

Zevra Therapeutics, Inc.

ZVRANASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure

Filed Nov 20, 2025Accepted Nov 20, 2025, 4:29 PM ESTCIK 1434647Accession 0001193125-25-289865

Company context

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values - patient centricity, integrity, accountability, innovation, and courage - which guide its efforts to deliver long-term value.

Current securities

ZVRANASDAQ · EQUITY · Current

Historical securities (1)

KMPHOTC · EQUITY · Historical · closed Dec 28, 2020

Recent company filings

Disclosure sections

Items 5.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 20, 2025, R. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. (the “Company”) notified the Company of his decision to resign from his position, effective December 31, 2025 (the “Separation Date”), in order to pursue other professional opportunities. In connection with Mr. Clifton’s resignation, the Company and Mr. Clifton entered into a Separation Agreement and General Release (the “Separation Agreement”). Pursuant to the Separation Agreement, following the Separation Date, Mr. Clifton will receive the separation benefits consisting of (i) an amount equal to 12 months of his annual base salary, payable in accordance with the Company’s normal payroll schedule, (ii) an annual bonus of 40% of his base salary, (iii) up to 12 months of Company-paid COBRA continuation coverage, and (iv) full vesting of his outstanding equity awards. The payments and benefits under the Separation Agreement are contingent upon Mr. Clifton’s continued compliance with certain restrictive covenants, including non-disparagement, confidentiality, non-competition, and non-solicitation provisions. The Company has commenced a search process to identify a chief financial officer.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 20, 2025, the Company issued a press release announcing the matters disclosed in Item 5.02. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Filed exhibits (1)

EX-99.1 (by filename) d78999dex991.htm

EX-99.1 2 d78999dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Zevra Therapeutics, Inc. Announces CFO Transition Celebration, FL - November 20, 2025 - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, 2025, in order to pursue other professional opportunities. “Since joining the Company in 2015, LaDuane has provided steady leadership and invaluable guidance, leaving a lasting impact on the Company,” said Neil F. McFarlane, Zevra’s Chief Executive Officer and President. “He has played a pivotal role in our journey as we navigated our transition from development stage into a commercial-stage company focused on rare disease and leaves Zevra with a strong financial foundation to support the next phase of our growth. On a personal note, I want to thank LaDuane for his unwavering dedication and partnership over the years.” “It has been a great honor to be a part of the Zevra journey,” said Mr.…

Open exhibit ↗

Get the free weekly BCS email.